Base the pharmacological treatment of post-stroke muscle spasticity on the needs and preferences of the patient
- … show all 0 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The pharmacological treatment of post-stroke muscle spasticity should be individualized according to several factors, including treatment objectives and the patient’s preferences. Botulinum neurotoxin is the first-line treatment, with peripheral nerve blocks being an option for spasticity of the proximal lower limb muscles. The use of oral muscle relaxants should be limited, as they are associated with the risk of generalized weakness and systemic adverse effects.
- Bakheit AMO. The pharmacological management of post-stroke muscle spasticity. Drugs Aging. 2012;29(12):941–7.
- Watkins CL, Leathley MJ, Gregson JM, et al. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16(5):515–22. CrossRef
- Lundström E, Smits A, Borg J, et al. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke. 2010;41(2):319–24. CrossRef
- Royal College of Physicians of London, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines. London: Royal College of Physicians; 2009.
- Ward AB, Aquilar M, De Beyl Z, et al. Use of botulinum toxin type A in management of adult spasticity: a European consensus statement. J Rehabil Med. 2003;35(2):98–9. CrossRef
- Yelnik AP, Simon O, Bensmail D, et al. Drug treatments for spasticity. Ann Phys Rehabil Med. 2009;52(10):746–56. CrossRef
- Simpson DM, Alexander DN, O’Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized double-blind placebo controlled trial. Neurology. 1996;46(5):1306–10. CrossRef
- Bakheit AMO, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb muscle spasticity after stroke. Stroke. 2000;31(10):2402–6. CrossRef
- Bakheit AMO, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb muscle spasticity in patients with stroke. Eur J Neurol. 2001;8(6):559–65. CrossRef
- Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. N Engl J Med. 2002;347(6):395–400. CrossRef
- Bakheit AMO, Ward CD, McLellan DL. Generalised botulismlike syndrome following intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry. 1997;62(2):198. CrossRef
- Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113(3):303–12. CrossRef
- Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol. 1995;2:17–8.
- Odergren T, Hjaltasaon H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose of equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64(1):6–12. CrossRef
- Blitzer A. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head Neck Surg. 2005;133(6):836–8. CrossRef
- Hatheway CH, Dang C. Immunogenicity of the neurotoxins of clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p. 93–107.
- Bakheit AMO, Liptrot A, Newton R, et al. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. Int J Rehabil Res. 2012;35(1):36–9. CrossRef
- Bakheit AMO, Badwan DAH, McLellan DL. The effectiveness of chemical neurolysis in the treatment of lower limb muscle spasticity. Clin Rehabil. 1996;10:41–4.
- Bradley LJ, Kirker SG. Pregabalin in the treatment of spasticity: a retrospective case series. Disabil Rehabil. 2008;30(16):1230–2. CrossRef
- Mueller ME, Gruenthal M, Olsen WL, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil. 1997;78(5):521–4. CrossRef
- Gruenthal M, Mueller ME, Olsen WL, et al. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord. 1997;35(10):686–9. CrossRef
- Cutter NC, Scott DD, Johnson JC. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled randomized trial. Arch Phys Med Rehabil. 2000;81(2):164–9.
- Zajicek J, Fox P, Sanders H, et al. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9295):1517–26. CrossRef
- Base the pharmacological treatment of post-stroke muscle spasticity on the needs and preferences of the patient
Drugs & Therapy Perspectives
Volume 29, Issue 5 , pp 145-148
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links